Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

• Status: Completed
• Trial end date: 2019-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhengzhou University
• Treatments: Apatinib

Criteria

Inclusion Criteria:

• Age range 14-70 years old; ECOG performance status 0-2.

• Estimated survival time > 6 months.

• Histological confirmed diffuse large B cell lymphoma.

• Have taken first-line chemotherapy regimen and failed.

• None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.

• At least one measurable lesion.

• None of other serious diseases, cardiopulmonary function is normal.

• Pregnancy test of women at reproductive age must be negative.

• Patients could be followed up.

• None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.

• Volunteers who signed informed consent.

Exclusion Criteria:

• Disagreement on blood sample collection.

• Patients allergic of any of drug in this regimen or with metabolic disorder.

• Pregnant or lactating women.

• Serious medical illness likely to interfere with participation.

• Serious infection.

• Primitive or secondary tumors of central nervous system.

• Chemotherapy or radiotherapy contraindication.

• The evidence of CNS metastasis.

• History of peripheral nervous disorder or dysphrenia.

• Patients participating in other clinical trials.

• Patients taking other antitumor drugs.

• Patients estimated to be unsuitable by investigator.